Rockwell Medical Inc

Emmaus Medical Inc., of Torrance, Calif., part of Emmaus Life Sciences Inc., named Timothy Cote regulatory advisor

Rockwell Medical Inc., of Wixom, Mich., said it priced a public offering of about 11.5 million shares of common stock at $3.05 per share, a 15 percent discount to Tuesday's closing price

3/29/13 OncoSec Medical Inc. (San Diego) ImmunoPulse and NeoPulse DNA-based immunotherapy and NeoPulse therapy Solid tumors Phase II data demonstrated durable response results that were positive 3/26/13 Oxford BioMedica plc (Oxford, UK) TroVax Therapeutic vaccine Malignant pleural mesothelioma Started a Phase II trial 3/14/13 PsiOxus Therapeutics Ltd. (Oxford, UK) MT-102 A small molecule Cancer cachexia Completed patient enrollment in its Phase II trial 3/5/13 SymBio Pharmaceuticals Ltd. (Tokyo

Credit Suisse First Boston, HBM Healthcare Investments Ltd., Vulcan Capital, Celgene, Delphi Ventures, Novo A/S and the Column Group also participated 3/8/13 Resverlogix Corp. (Calgary, Alberta) Loan agreement N/A $38.8 Resverlogix amended and restated a loan agreement with Citibank NA, increasing the loan to $38.8M 3/12/13 Rockwell Medical Inc. (Wixom, Mich.) Registered direct offering 4.3S $12.9 Rockwell is selling 4.3M common shares at $3 each to raise $12.9M

Rockwell Medical Inc

Rockwell Medical Inc., of Wixom, Mich., closed a sale of 4.3 million shares of common stock at $3 per share in a registered direct offering for an aggregate amount of $12.9 million

Third Rock also invests in medical device companies, among them DC Devices, NinePoint Medical Inc

OncoSec Medical Inc., of San Diego, reported positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial of its ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors

Rockwell Medical Inc

Rockwell Medical Inc., of Wixom, Mich., will sell 4.3 million common shares at $3 per share in a registered direct offering for a total of about $12.9 million

a high capacity non-absorbed oral potassium binder Hyperkalemia in chronic kidney disease First patient was enrolled in its pivotal Phase III study 2/21/13 rEVO Biologics (Framingham, Mass.) Atryn Anti-thrombin Recombinant therapy Hereditary antithrombin deficiency Phase III data showed benefit for pregnant patients 2/19/13 Rockwell Medical Inc. (Wixon, Mich.) SFP Soluble ferric pyryphosphate

OncoSec Medical Inc., of San Diego, appointed Sanjiv S. Agarwala, Axel Hauschild, Kim A. Margolin and Vernon K. Sondak to its new melanoma advisory board (MAB) and named Adil I. Daud chairman of the MAB

Ironically, Xyrem was the focus of an unrelated biotech dispute last year, when a federal appeals court threw out the conviction of Alfred Caronia, a former sales representative with Orphan Medical Inc. – later acquired by Jazz – who claimed his First Amendment rights were violated for promoting Xyrem in conditions not included in the label

Ironically, Xyrem was the focus of an unrelated biotech dispute last year, when a federal appeals court threw out the conviction of Alfred Caronia, a former sales representative with Orphan Medical Inc. – later acquired by Jazz – who claimed his First Amendment rights were violated for promoting Xyrem in conditions not included in the label

Rockwell Medical Inc., of Wixon, Mich., reported top-line results from the PRIME study of soluble ferric pyryphosphate (SFP), its iron delivery drug in Phase III testing for the treatment of iron deficiency in hemodialysis patients

In 2008, a jury found Alfred Caronia guilty of promoting the narcolepsy drug Xyrem (sodium oxybate) for conditions not included in the label gained by Orphan Medical Inc. (acquired by Jazz Pharmaceuticals plc